Press Releases Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-16 pm EST			5-day change	1st Jan Change
38.83 ^USD	-0.23%		+0.03%	+12.85%

Dec. 16	Harmony Biosciences, Beacon Biosignals Collaborate on Phase 3 Trials in Narcolepsy, Hypersomnia	MT
Dec. 16	Beacon Biosignals announces partnership with Harmony Biosciences	RE

Press Releases

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG	Dec. 16	AQ
Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome	Dec. 08	BU
Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting	Dec. 02	BU
Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation	Nov. 24	BU
Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence	Nov. 19	BU
Harmony Biosciences to Participate in Upcoming Investor Conferences	Nov. 18	BU
Harmony Biosciences : HRMY Q3 2025 Earnings Presentation	Nov. 04	PU
Harmony Biosciences : HRMY Q3 2025 Financial Business Update FINAL 1021AM	Nov. 04	PU
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M	Nov. 04	BU
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance, Raises 2025 Revenue Guidance	Oct. 24	AQ
Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance	Oct. 23	BU
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome	Sep. 24	BU
Harmony Biosciences Spotlights Project Sleep's Hollywood Initiative for Promoting Realistic Sleep Disorder Portrayals in Film and Television	Sep. 23	AQ
Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress	Aug. 26	BU
Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference	Aug. 21	BU
Harmony Biosciences : HRMY Q2 2025 Earnings Presentation FINAL	Aug. 05	PU
Harmony Biosciences : HRMY Q2 2025 Financial Business Update FINAL	Aug. 05	PU
Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025	Aug. 05	BU
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025	Jul. 24	AQ
Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025	Jul. 22	BU
Harmony Biosciences to Participate in H.C. Wainwright HCW@Home Series	Jul. 16	AQ
Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series	Jul. 15	BU
Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025	Jun. 11	BU
Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation	Jun. 05	BU
Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference	Jun. 04	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Pharmaceuticals

Press Releases

Filters